Evolving Standards of HER2-Positive Breast Cancer

Clinical Pearls

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses evolving standards of early stage HER2-positive breast cancer.

• The treatment of HER2-positive breast cancer has come a long way since the discovery that the addition of trastuzumab leads to improvement in disease-free and overall survival.
• Moving forward, the focus should not be just on improving the endpoints of disease-free and overall survival, but also defining the patient population at the highest risk.
• There remains a need to determine how patients can be treated better with less treatment.

<<<

Back to the 2014 Breast Cancer Symposium conference page